药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)
Contextual fear conditioning model,317–318, 318f 318
Contract research organizations (CROs),457–460 460
Cyan fluorescent protein (CFP), 170–171 171
Cyclic adenosine monophosphate (cAMP) 0
signaling, 109–110, 109f, 134–135 135
Cyclooxygenase-1 (COX-1), 524–525 525
Cyclooxygenase-2 (COX-2), 415–416,524–525 525
Lind, James, 383–384, 384f 384
Liver microsomal stability 0
human liver microsome (HLM) stability,279–280, 280f, 282–283, 283f 283
mouse liver microsomes (MLM),280–281, 281f 281
rat liver microsomes (RLM), 279–282,280f, 282f 282
X-ray crystal-based models, 19 19
HMG-CoA reductase inhibitors, 13–14,16–18, 16f 16
Homologous animal models, 312 312
HSP90 inhibitors. See Heat shock protein90 (HSP90) inhibitors 0
Human chorionic gonadotropin (hCG), 424 424
Human Genome Project, 87 87
Human genomes, 87, 88f 88
Human immunodeficiency virus (HIV), 1 1
protease inhibitors, 169, 169f 169
Crixivan® (Indinavir), 508–510, 508f,510f 510
Human liver microsome (HLM) stability,279–280, 280f, 282–283, 283f 283
Human serum albumin (HSA), 268–269 269
Hypercholesterolemia, diet-induced model. 0
See Animal models, disease states, 0
cardiovascular disease animal 0
Hyperlipidemia. See Animal models, 0
disease states; cardiovascular 0